ELAVL1 (HuR) is an RNA-binding protein that primarily functions to stabilize target mRNAs by binding to AU-rich elements (AREs) and poly-U elements in their 3'-UTRs 1. The protein promotes mRNA stability through direct interaction with specific sequence motifs, particularly the 5'-UUUU[AG]UUU-3' motif 1. ELAVL1 regulates diverse cellular processes including autophagy, where it binds to BECN1 mRNA 3'-UTR to enhance autophagosome formation and autophagic flux, ultimately promoting ferroptosis in hepatic stellate cells 2. The protein also modulates alternative splicing through interactions with other RNA-binding proteins; for instance, it cooperates with CMTR1 to regulate CD44 alternative splicing in gastric cancer 3 and works with IGF2BP proteins to control SNRPA expression, affecting DNA repair pathways 4. In disease contexts, ELAVL1 exhibits dual roles: it can promote cancer progression by stabilizing oncogenic mRNAs and enhancing drug resistance 1, but also facilitates beneficial ferroptosis in liver fibrosis treatment 2. The protein's expression is regulated through various mechanisms including transcriptional control and post-translational modifications, and its dysregulation is associated with poor clinical outcomes in multiple cancer types 1. ELAVL1 also participates in complex regulatory networks, such as the LINC00941-ELAVL1 axis that controls autophagy-related gene stability in pulmonary fibrosis 5.